Mucuna pruriens (Velvet bean) Rescues Motor, Olfactory, Mitochondrial and Synaptic Impairment in PINK1(B9) Drosophila melanogaster Genetic Model of Parkinson's Disease by Poddighe S et al.
Mucuna pruriens (Velvet bean) Rescues Motor, Olfactory,
Mitochondrial and Synaptic Impairment in PINK1B9
Drosophila melanogaster Genetic Model of Parkinson’s
Disease
Simone Poddighe1., Francescaelena De Rose2., Roberto Marotta3., Roberta Ruffilli3, Maura Fanti1,
Pietro Paolo Secci4, Maria Cristina Mostallino4, Maria Dolores Setzu1, Maria Antonietta Zuncheddu2,
Ignazio Collu2, Paolo Solla5, Francesco Marrosu5, Sanjay Kasture6, Elio Acquas2,7,8, Anna Liscia2*
1Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy, 2Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy, 3 Electron
Microscopy Lab, Nanochemistry Department, Istituto Italiano di Tecnologia, Genoa, Italy, 4 Institute of Neuroscience, National Research Council, Cagliari, Italy,
5Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy, 6 Sanjivani College of Pharmaceutical Education and Research,
Kopargaon, Ahmednagar, Maharashtra, India, 7Center of Excellence for the Study of Neurobiology of Addiction, University of Cagliari, Cagliari, Italy, 8National Institute of
Neuroscience - INN, University of Cagliari, Cagliari, Italy
Abstract
The fruit fly Drosophila melanogaster (Dm) mutant for PTEN-induced putative kinase 1 (PINK1B9) gene is a powerful tool to
investigate physiopathology of Parkinson’s disease (PD). Using PINK1B9 mutant Dm we sought to explore the effects of
Mucuna pruriens methanolic extract (Mpe), a L-Dopa-containing herbal remedy of PD. The effects of Mpe on PINK1B9
mutants, supplied with standard diet to larvae and adults, were assayed on 3–6 (I), 10–15 (II) and 20–25 (III) days old flies.
Mpe 0.1% significantly extended lifespan of PINK1B9 and fully rescued olfactory response to 1-hexanol and improved
climbing behavior of PINK1B9 of all ages; in contrast, L-Dopa (0.01%, percentage at which it is present in Mpe 0.1%)
ameliorated climbing of only PINK1B9 flies of age step II. Transmission electron microscopy analysis of antennal lobes and
thoracic ganglia of PINK1B9 revealed that Mpe restored to wild type (WT) levels both T-bars and damaged mitochondria.
Western blot analysis of whole brain showed that Mpe, but not L-Dopa on its own, restored bruchpilot (BRP) and tyrosine
hydroxylase (TH) expression to age-matched WT control levels. These results highlight multiple sites of action of Mpe,
suggesting that its effects cannot only depend upon its L-Dopa content and support the clinical observation of Mpe as an
effective medication with intrinsic ability of delaying the onset of chronic L-Dopa-induced long-term motor complications.
Overall, this study strengthens the relevance of using PINK1B9 Dm as a translational model to study the properties of Mucuna
pruriens for PD treatment.
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Introduction
Parkinson’s disease (PD) is, after the Alzheimer’s disease, the
second most prevalent neurodegenerative disease first affecting
medulla oblongata, olfactory bulb and substantia nigra [1]. Loss of
olfaction is a very consistent marker of PD occurring in 95% of
patients early before the onset of motor symptoms [2]. Olfactory
dysfunction is observed in PTEN-induced putative kinase 1
(PINK1B9) Parkinsonism, both in humans [3] and in animal
models of PD [4]. The Drosophila melanogaster (Dm) PINK1B9
mutant model recapitulates several of the essential features of PD
[5] and has been used to study neuronal dysfunction and
molecular aspects of neurodegeneration [6]. In particular,
PINK1B9 model provides major information regarding pathogen-
ic molecular basis of early onset PD and mitochondrial dysfunc-
tion [5]. Accordingly, it was recently reported that PINK1
mutation enhances mitochondrial stress-induced neurodegenera-
tion in mice [7].
L-Dopa is the most effective symptomatic medication of PD and
is still considered the gold standard in its treatment, although other
drugs such as dopamine (DA) agonists, DA uptake and mono
amino oxidase-B inhibitors are commonly used in the clinical
management of PD patients [8] [9] [10]. Besides, other drugs such
as adenosine A2A antagonists used as adjunct might be effective in
the symptomatic treatment of PD [11]. In addition, the
involvement of non-dopaminergic neurotransmitters such as
noradrenaline, serotonin, glutamate, and acetylcholine in different
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brain areas like cortex, brainstem and basal ganglia has prompted
many researchers to investigate the effects of non-dopaminergic
drugs [12] indicating the involvement of multiple targets in
treatment of PD.
Several reports on antiparkinsonian activity ofMucuna pruriens
(Mp) [13] [14] endorse the use of Mp seeds in PD. In addition to
L-Dopa, Mp seeds contain genistein and polyunsaturated fatty
acids which support its antiparkinsonian and neuroprotective
actions [15]. Furthermore, phytic acid, another Mp constituent
with antioxidant and iron sequestrant activity, has been reported
to suppress methyl-phenyl-tetrahydropyridine (MPTP) induced
hydroxyl radical generation [16]. Hence, in view of multiple
phytoconstituents supporting antiparkinsonian activity of Mp, the
present study was aimed at verifying if Mpe’s ability to ameliorate
symptoms in this PD model might be attributable to L-Dopa only
or to the Mp extract as a whole in which L-Dopa is present along
with other ingredients. On these bases we evaluated the
antiparkinsonian profile of the standardized methanolic extract
of the seeds of Mp (Mpe) on lifespan, climbing activity and
olfactory function in PINK1B9 as compared to either wild type
(WT) and untreated PINK1B9 Dm. In addition, in order to gain
mechanistic insights on the neuroprotective and neuro-rescue
properties of Mpe, we also evaluated the expression of bruchpilot
protein and tyrosine hydroxylase, as well as the morphology of
presynaptic active zones and mitochondria in flies’antennal lobes,
i.e. the olfactory bulbs-equivalent structure, and thoracic ganglia,




For these experiments we used adult wild type (WT) Oregon-R
(Oregon-R-C) andPTEN-induced putative kinase 1PINK1B9 (w[*]
Pink1[B9]) mutant Drosophila melanogaster (Dm) males (from
Bloomington Stock Center; Fly Base: http://flybase.bio.indiana.
edu). After emergence from pupae, maleWT andPINK1B9mutant
flies were separated.WT andmutant flies were reared on a standard
cornmeal-yeast-agar medium in controlled environmental condi-
tions (24–25uC; 60% relative humidity; light/dark = 12/12 hours).
In detail, four groups of mutant flies were reared on a standard
medium supplemented with Mucuna pruriens methanolic extract
(Mpe) (Batch no. FMPEX/2012060001; Natural Remedies Ltd.,
Bangalore, India). PINK1B9 mutants were supplied with Mpe at
different concentrations (0 (i.e. untreated PINK1B9mutants), 0.1, 1
and 10% w/w in their standard diet) both as larvae and adults (L+/
A+). In addition, another group was reared on a standard medium
supplemented with 0.01% (0.5 mM) L-Dopa (Sigma Aldrich,
Milan, Italy), a percentage similar to that at which L-Dopa was
supplemented with 0.1%Mpe [15]. The effects ofMpewere assayed
at different age steps (I: 3–6; II: 10–15; III: 20–25 days old). A series
of experiments on life span, using various concentrations ofMpe (see
below in Survival curves) provided the basis for selecting the optimal
concentration at which conduct the behavioral, morphological, and
protein expression assessments. In particular, based on lifespan
results, the olfaction behavior assessments, transmission electron
microscopy (TEM) and western blot analyses were restricted to
group II flies after 0.1% Mpe administration as L+/A+. Standard
genetic procedures were used during the study.
Survival curves
With the aim of selecting the optimal Mpe’s concentration, Dm
were grown on standard diet supplemented with different
concentrations of Mpe at 25uC. Cohorts of 40 flies (4 flies/tube)
from each experimental group (i.e. WT, untreated and Mpe-
treated PINK1B9) were monitored every 2 days for their survival.
Mortality was analyzed using Kaplan-Meier survival curves and
the statistical comparisons were made with a Gehan-Breslow-
Wilcoxon test. Experiments were done in duplicate with the
exception of those on WT, untreated mutants, 0.1% Mpe- and
0.01% L-Dopa-treated PINK1B9 that were done in triplicate.
Each experiment was conducted with the appropriate control
group (i.e. WT, untreated PINK1B9 and treated PINK1B9).
Climbing assay
The climbing assay (negative geotaxis assay) was used to assess
locomotor ability [17]. Climbing data were obtained from groups
I–III of untreated WT, untreated PINK1B9 and, as L+/A+, 0.1, 1
and 10% Mpe- and 0.01% L-Dopa-treated PINK1B9 mutants.
Cohorts of 30 flies from each experimental group were subjected
to the assay. Flies were placed individually in a vertically-
positioned plastic tube (length 10 cm; diameter 1.5 cm) and
tapped to the bottom. Climbing time was recorded upon crossing a
line drawn at 6 cm from the bottom. The number of flies that
could climb unto, or above, this line within 10 seconds was
recorded and expressed as percentage of total flies. Data were
expressed as average + SEM from at least three separate
experiments. The statistical evaluation was made by two-way
ANOVA (p,0.05) followed by HSD post-hoc test.
Electroantennograms (EAGs) recordings
In vivo electroantennogram recordings (EAG) were performed
following a previously described protocol [4]. Briefly, live adult
WT Dm and untreated, Mpe- and L-Dopa-treated PINK1B9 from
group II (n = 12/each strain) were singly positioned under the view
of an Olympus BX51WI light microscope (Olympus, Tokyo,
Japan). Electrodes were silver wires inserted in glass capillaries
filled with a saline solution (NaCl 150 mM).The recording glass
electrode was positioned on the tip of the left antenna while the
reference was pierced through the compound eye. The EAG signal
was amplified with an AC/DC probe and then acquired with an
IDAC-4 interface board (Syntech, Hilversum, NL). The antennae
were constantly blown by a flow of charcoal purified and
humidified air (speed 0.5 m/s) via a glass tube. Odor stimuli were
administered by injecting a puff of purified air (0.5 s at 10 mL/s
airflow) through the pipette using the stimulus delivery controller
(Syntech, Hilversum, NL).
Odor stimuli were prepared in 3 step-dose concentration (0.01,
0.1, and 1% v/v) diluted in hexane. Odor stimulus, 1-hexanol, was
chosen according to Fishilevich and Vosshall [20], for its well-
known stimulant activity in Dm. Mean values of EAG amplitude
were calculated and then analyzed by comparing the results
obtained in untreated PINK1B9, Mpe- and L-Dopa-treated flies
with matched WT. The significance of differences was tested by
one-way ANOVA (followed by HSD post hoc test) with a
threshold level of statistical significance set at p,0.05. EAG
results are expressed as average values 6 S.E.M and represented
by histograms.
Olfactory behavior
Free-walking bioassay was performed following the experimen-
tal procedures used by Dekker et al. [18]. In particular, group II
WT, untreated PINK1B9 and, as L+/A+, 0.1% Mpe- and 0.01%
L-Dopa-treated PINK1B9 mutants were given the opportunity to
choose between vials containing water with or without odor. Two
4 mL glass vials were placed symmetrically in a large petri dish
(arena) and then fitted with truncated pipette tips. The vials were
filled with 300 mL of water with 0.25% Triton X (Sigma-Aldrich,
Mucuna in a Drosophila Parkinson’s Disease Model
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Milan, Italy) with or without the odorant (0.1% (v/v) 1-hexanol;
Sigma-Aldrich, Milan, Italy). As mentioned above, in order to
allow detection of possible Mpe’s effects independently from the
circuit, octopaminergic -for appetitive- and dopaminergic -for
aversive stimuli [19], 1-hexanol was chosen, according to Fish-
ilevich and Vosshall [20], because the mechanism(s) of olfactory
transduction signal involve several glomeruli and complex neural
pathways. Flies were starved for 8 hours prior to starting the
experiments. These, done in triplicate, were performed in
controlled environmental conditions (n = 12 bioassays/each ex-
perimental group of flies; n = 20 flies/arena). The assays lasted 18
hours, a streamlined range of time to overtake the possible
influence of motor impairment in mutants. The dehydration of
flies was prevented by placing a cotton ball with 3 mL of water in
the arenas. Data obtained were expressed as average of
percentages of flies reaching the 1-hexanol or water trap and
statistically evaluated by one-way ANOVA (p,0.05) followed by
HSD post-hoc test.
Electron microscopy analysis
Group II WT, untreated PINK1B9 and, as L+/A+, 0.1% Mpe-
treated PINK1B9 mutants were anesthetized using carbon dioxide
and carefully decapitated. The brains and the thoracic ganglia,
once rapidly removed, were fixed in a mixture of 2% glutaralde-
hyde and 2% paraformaldehyde in 0.1 M cacodylate buffer,
washed several times in the same buffer, post-fixed in 1% osmium
tetroxide in distilled water for 2 hours, and stained overnight at
4uC in an aqueous 0.5% uranyl acetate solution. After several
washes in distilled water, the samples were dehydrated in a graded
ethanol series, and embedded in SPURR resin. To identify the
antennal lobes (ALs), semi-thin coronal sections of the whole
brains were cut with a Leica EM UC6 ultramicrotome, stained
with toluidine blue and observed with a Leica DM2700 P light
microscope. Sections of about 70 nm corresponding to portions of
the ALs and thoracic ganglia were cut with a diamond knife on a
Leica EM UC6 ultramicrotome. Transmission electron microsco-
py (TEM) images were collected with a FEI Tecnai G2 F20 (FEI
Company, The Netherlands) and a Jeol JEM 1011 (Jeol, Japan)
electron microscopes, working respectively at an acceleration
voltage of 80 and 100 kV, and recorded with a 1 and 2 Mp
charge-coupled device (CCD) camera (Gatan BM Ultrascan and
GatanOrius SC100, respectively). T-bars density (expressed as
number of T-bars/m2) in both ALs and thoracic ganglia
presynaptic boutons was assessed on a total of ten animals (three
WT, three untreated PINK1B9 and four 0.1% Mpe-treated
PINK1B9 mutants). 459 and 683 T-bars were randomly sampled
respectively in the ALs and the thoracic ganglia on a total 496
non-overlapping micrographs at a final magnification of 6000,
corresponding to a total sampled area of more than 6000 mm2. T-
bars were unambiguously identified at presynaptic active zones by
the presence of T-shaped electron-dense projections typically
tethered by a large number of presynaptic vesicles.
The number of damaged mitochondria within ALs (expressed as
percentage of the total number of mitochondria/sampled area)
was evaluated in WT, untreated PINK1B9 and 0.1% Mpe-treated
PINK1B9 mutants. More than 3000 mitochondria were randomly
sampled on 191 non-overlapping micrographs at a final magni-
fication of 4000, corresponding to a total sampled area of more
than 5000 mm2. Damaged mitochondria were recognized for the
presence of swollen external membrane, clearly fragmented cristae
and inhomogeneous electron transparent mitochondrial matrix.
The mean differences were tested using a two tailed t-test and a
p,0.01 level was considered statistically significant.
Protein extraction and western blot analysis
Group II WT, untreated PINK1B9 and, as L+/A+, 0.1% Mpe-
and 0.01% L-Dopa-treated PINK1B9 mutants flies were collected
and immediately stored at 280uC. Head lysate preparations of
adult males were performed by homogenization in RIPA buffer
(9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L monobasic
sodium phosphate, 150 mmol/L sodium chloride, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate [pH
adjusted to 7.4]) containing fresh protease inhibitor cocktails
(Sigma-Aldrich, St. Louis, MO, USA). Two centrifugations were
performed at 4uC at 10,000 g for 15 minutes, before protein
quantification by DC Protein assay (Biorad, Hercules, CA, USA).
20 mg of proteins were resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis analysis using the mini-PRO-
TEIN 3-electrophoresis module assembly (Biorad, Hercules, CA,
USA) and then transferred to immobilon-polyvinylidenedifluoride
membranes (Amersham Biosciences). The membranes were
incubated with primary antibodies overnight at 4uC. Immune
complexes were detected with horseradish peroxidase–conjugated
secondary antibodies and chemiluminescence reagents (ECL,
Amersham Biosciences) and visualized by Image Quant LAS
4000. Densitometric analysis was performed by Image Studio Lite
software for quantitative assessment.
Primary antibodies used in this study were against nc82 (1:100
dilution, DSHB); Tyrosine Hydroxylase (1:1000 dilution, MAB
318 Merk Millipore); actin (1:100, sc1616 Santa Cruz Biotech-
nology); Horseradish-peroxidase–conjugated secondary antibodies
were purchased from Life Technologies. Statistical significance of
the results was evaluated by one-way ANOVA (p,0.05) followed
by a HSD post-hoc test.
Results
Effects of Mucuna pruriens and L-Dopa on life span of
PINK1B9 mutants
As shown in Fig. 1A, in agreement with our previous report [4],
PINK1B9 mutants displayed a significantly shorter lifespan with
respect to WT flies. To assess the ability ofMpe to affect lifespan of
PINK1B9 mutants, they were supplied Mpe at different concen-
trations (0 (untreated), 0.1, 1 and 10% w/w in their standard diet)
both as adults only (L2/A+) (Fig. 1B and Fig. S1A), and as larvae
and adults (L+/A+) (Fig. 1C and Fig. S1B). The effects of L-Dopa
(supplied as L+/A+ (at the concentration, 0.01%, at which is
present in the Mpe 0.1%) on life span of PINK1B9 are also
reported in Fig. 1D. The comparison between untreated andMpe-
treated PINK1B9, as shown by Kaplan-Meier survival curves,
revealed a statistically significant effect of Mpe on lifespan of
PINK1B9 mutants only when L+/A+ flies were fed 0.1% Mpe
(Fig. 1C, p,0.05 by Gehan-Breslow-Wilcoxon test). No effect was
observed following the L-Dopa administration in L+/A+. As shown
in Fig. S1A, no significant effects were detected in in L2/A+ flies,
no matter the concentration tested, nor in L+/A+ flies fed 1% or
10% Mpe enriched standard diet (Fig. S1B).
Mucuna pruriens rescues impaired climbing behavior of
PINK1B9 mutants
To investigate the locomotor ability the negative geotaxis assay,
as described previously [17], was used. An impairment of climbing
behavior was observed in untreated PINK1B9 at different age
steps (I: 3–6; II: 10–15; III: 20–25 days old) with a worsening trend
with aging, while WT flies fulfilled the evaluation criterion without
differences among age groups. As shown in Fig. 2A, the mutants
took longer times to accomplish the task than the WT (p,0.001).
Mucuna in a Drosophila Parkinson’s Disease Model
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The Mpe 0.1% treatment significantly ameliorated the climbing
activity in mutants and also reduced the worsening trend with
aging although the score obtained by treated mutants still
remained higher than that measured in WT. Interestingly, the
climbing time of L-Dopa-treated mutants from groups I and III
did not significantly differ with respect to age-matched untreated
PINK1B9, the performance of only group II flies being signifi-
cantly ameliorated.
As shown in Fig. 2B, L+/A+ 1% Mpe-treated mutants reached
similar rescue of climbing activity as observed in 0.1% Mpe-
treated ones only when tested at early ages (groups I and II). On
the other hand, 10% Mpe administration failed to significantly
ameliorate motor behavior in groups I and III with respect to
untreated PINK1B9 mutants, while a significant effect was
detected in treated flies from group II. We also considered the
percentages of flies that were able to complete the test and the
results are depicted in histograms shown in Fig. 2C and D. In this
respect, most of WTs of all age steps (97–98%) were able to
complete the test, while only 76% of PINK1B9 from group I, 46%
from group II and 36% from group III accomplished it, showing a
clear age-dependent worsening. Administration of 0.1% Mpe, as
L+/A+, greatly rescued PINK1B9 mutants (groups I–III) from
motor impairment and restored to WT values the percentages (86–
94%) of flies able to accomplish the task according to the
evaluation criterion (10 sec). Furthermore, at variance with the
above results, the effects of L-Dopa worsened over time. In
particular, 0.01% L-Dopa administration determined a decrease
of the number of flies able to complete the task showing a negative
trend with aging. In fact, percentages of flies were 91%, 82% and
62%, in groups I, II and III, respectively.
Mucuna pruriens and L-Dopa effects on the EAG
amplitude
As expected, the olfactory stimulations of flies’ antennae elicited
responses with the typical EAG wave form, i.e. a rapid
depolarization followed by a slower recovery phase, ending with
the hyperpolarized wave before complete reversal to the baseline.
The results, summarized in Fig. 3A and 3B, show the olfactory
response to 1-hexanol (0.01, 0.1 and 1%) elicited in WT, untreated
PINK1B9, 0.1% Mpe- and 0.01% L-Dopa-treated mutants from
age group II. In details, the average EAG signal amplitudes evoked
by stimuli were significantly lower in PINK1B9 specimens in
respect to WT thus substantially confirming data previously
reported [4].
The stimulation with 1-hexanol at 1% did not elicit a significant
increase in the EAG amplitude as compared with the stimulation
at 0.1% in all strains of flies with the exception of mutants flies
treated with L-Dopa 0.01%. This result indicates that at the
highest odor concentrations (0.1 and 1%) a saturation of response
was reached by all groups but by the L-Dopa treated mutants.
Besides, we observed that the responses to stimuli in WTs elicited a
greater hyperpolarized phase in the EAGs (Fig. 3B and S2).
Even if a positive trend in treated mutants exists in the signal
amplitude in response to 1-hexanol, a statistical difference between
Figure 1. Effects of Mpe and L-Dopa on lifespan. (A): Lifespan, expressed as % survival rates, of wild type (WT) and PINK1B9 flies. (B) and (C):
Lifespan of PINK1B9 treated with Mucuna pruriens extract (Mpe) 0.1%,only when adults (L2/A+) (panel B) or from their larval stage to the end of their
life-cycle (L+/A+) (panel C), respectively, as compared to lifespan of untreated PINK1B9 flies. (D): Lifespan of PINK1B9 flies treated with L-Dopa (L+/A+)
0.01%. *indicates p,0.05 at Kaplan-Meier survival curves (Gehan-Breslow–Wilcoxon - GraphPad Prism 5.01) between WT and untreated PINK1B9 (A)
and between untreated PINK1B9 and PINK1B9 fed Mpe 0.1% (C).
doi:10.1371/journal.pone.0110802.g001
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untreated, Mpe- and L-Dopa-treated PINK1B9 was not detected.
The lowest odor concentration tested elicited a significantly higher
response in WT as compared to the all strains of mutants (p,
0.05). This difference shrank when the 0.1% concentration of odor
was administered. A reduced response, although not statistically
significant (p.0.05), was still detected in untreated mutants with
respect to WTs (p,0.05), while treated flies showed on average an
increased response with respect to untreated flies. The response
measured in treated flies was therefore halfway between the
highest of WTs and the lowest of untreated PINK1B9. Samples of
EAGs responses are shown in Fig. 3B and Fig. S2.
Mucuna pruriens rescues impaired olfactory behavior
The olfactory behavior assay was restricted to flies of group II,
by testing the responses to 1-hexanol (0.1% v/v) of WT, untreated
PINK1B9, 0.1% Mpe- and 0.01% L-Dopa-treated, as L+/A+,
PINK1B9 mutants. As expected, the analysis of the result, shown
in Fig. 4, confirmed the olfactory behavioral impairment in
PINK1B9 flies [4]. In fact, only 29.664.4% of mutant flies were
odor-trapped, while the percentage of baited WT (52.966.6%)
was significantly higher (p,0.004). PINK1B9 flies treated with
0.1% Mpe and 0.01% L-Dopa were able to reach the stimuli as
WT controls (p.0.05). In fact, percentages of trapped flies were
45.265.8% and 44.263.6% for 0.1% Mpe- and 0.01% L-Dopa-
treated mutants, respectively. Similar results were obtained
concerning the numbers of trapped flies in the blank bait (H2O)
(p,0.05 between untreated PINK1B9with respect to WT, 0.1%
Mpe- and 0.01% L-Dopa-treated mutants).
Figure 2. Effects of Mpe and L-Dopa on climbing activity. (A): Climbing activity of adult males wild-type (WT), untreated PINK1B9, PINK1B9
treated with Mucuna pruriens extract (Mpe) 0.1% and PINK1B9 treated with L-Dopa 0.01% (L-Dopa 0.01%). (B): Climbing activity of PINK1B9 adult males
treated with Mpe 1 and 10% as compared with WT and untreated PINK1B9. (A) and (B): Treatments were administered to flies from their larval stage to
the end of their life-cycle (L+/A+) and their effects were assayed at three different age steps (I: 3–6; II: 10–15; III: 20–25 days) of flies’ life-span. Values
are average + SEM. *indicates p,0.05 at two-way ANOVA followed by HSD post-hoc test as compared to WT; **indicates p,0.05 at two-way ANOVA
followed by HSD post-hoc test as compared to PINK1B9; ***indicates p,0.05 at two-way ANOVA followed by HSD post-hoc test as compared to
PINK1B9 Mpe 0.1%. (C) and (D): Percentages of adult males WT, PINK1B9, Mpe 0.1%, L-Dopa 0.01% (C) and Mpe 1 and 10% (D) that could climb unto, or
above, the line drawn at 6 cm from the bottom of the tube within 10 seconds.
doi:10.1371/journal.pone.0110802.g002
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Mucuna pruriens rescues loss of T-bars at active zones of
presynaptic terminals and damaged mitochondria in the
antennal lobes and thoracic ganglia
Transmission electron microscopy (TEM) analysis was restricted
to flies of group II of untreated WT, untreated PINK1B9 and
0.1% Mpe-treated, as L+/A+, PINK1B9 mutants and results are
shown in Fig. 5. A significant decrease of T-bars density was
observed in the presynaptic bouton active zones of both ALs and
thoracic ganglia of PINK1B9 mutants with respect to WT controls
(panels A, B, E and F). More importantly, a significant increase of
T-bars density was detected in the ALs and thoracic ganglia of
PINK1B9 treated with 0.1% Mpe, as L+/A+, with respect to
untreated PINK1B9 (panels A, B, E and F). Moreover the number
of damaged, swollen and with clearly fragmented cristae,
mitochondria was significantly lower in presynaptic boutons of
ALs of PINK1B9 mutants treated with 0.1% Mpe, compared with
untreated mutants (panels C, D and G).
Mucuna pruriens and L-Dopa differentially affect whole
brain bruchpilot (BRP) and tyrosine hydroxylase (TH)
expression
Fig. 6 shows the results of western blot analysis of whole brain
expression of BRP and TH of flies of group II WT, untreated
PINK1B9 0.1% Mpe- and 0.01% L-Dopa-treated, as L+/A+,
PINK1B9 mutants. As shown in Fig. 6A, the expression of BRP
and TH in untreated PINK1B9 mutants was significantly lower
(p,0.05) than in WT. Diet supply of 0.1% Mpe to PINK1B9
mutants significantly recovered BRP and TH expression to WT
controls levels (p,0.05) and these values did not differ statistically
from those of WT. Notably, BRP and TH expression in PINK1B9
mutants fed 0.01% L-Dopa resulted similar to BRP and TH
expression in untreated PINK1B9 mutants. ANOVA also revealed
that both BRP and TH expression resulted statistically different as
compared to their expression of both WT and PINK1B9 mutants
fed 0.1% Mpe.
Discussion
This study was aimed at characterizing the effects of the
standardized extract ofMucuna pruriens seeds, known for possible
neuroprotective effects in neurotoxin-induced models of PD [21]
[22] and reduced risk of dyskinesias [14], in a genetic fly model of
PD, the PINK1B9 mutant Dm [23]. Notably, mutations at PINK1
gene model a number of features of early onset PD such as cell
energy maintenance [24] and compromised olfactory and
mitochondrial function [4] enabling in-depth investigations into
physiopathology of PINK1B9-related molecular, morphological
and functional bases of PD. The present results show that addition
of 0.1% Mpe to the feeding medium of PINK1B9 mutants
Figure 3. Electroantennogram responses to 1-hexanol. Histograms in (A) show the dose-response relationship and their differences in signal
for olfactory stimulations in WT, untreated PINK1B9 and in Mpe (0.1%)- and L-Dopa (0.01%)-treated PINK1B9, recorded in flies from group II. As odor
stimuli, the 1-hexanol was administered in a 3-step dose from 0.01 to 1% in hexane. Values are average + SEM. *indicates p,0.05 at one-way ANOVA
followed by HSD post hoc test as compared to the previous concentration of the stimulus. **indicates p,0.05 at one-way ANOVA followed by HSD
post-hoc test as compared to WT. (B) Samples of EAGs recordings in response to 1-hexanol 0.1%.
doi:10.1371/journal.pone.0110802.g003
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significantly a) improved climbing ability and olfaction, b) rescued
compromised T-bars density and damaged mitochondria in the
ALs and thoracic ganglia, c) restored to WT control values the
expression of BRP and TH proteins. Moreover, these results
suggest that Mpe is an effective medication with intrinsic ability of
delaying the onset of chronic L-Dopa-induced long-term motor
complications (Fig. 2A and B).
These findings are in general agreement with previous studies
reporting antiparkinsonian activity ofMp [14] [25] associated with
reduced risk of dyskinesias, both in the clinical [26] and in the
experimental [14] setting, and suggest that its antiparkinsonian
effects may be due to components other than L-Dopa or that its
components might have L-Dopa-enhancing effects [25] [26] [27]
on one hand, as well as L-Dopa-induced dyskinesias (LID)-
preventive effects, on the other.
Intriguingly, PINK1B9 mutations have been linked to both
autosomal recessive and sporadic forms of PD and, given the role
of PINK1-parkin pathway in regulating mitochondrial function,
our findings highlight its role as a potential target for the described
actions of Mpe [30] on mitochondria. This interpretation finds
further support in the observation of mitochondrial stress-
dependent neurodegeneration [7] and dysfunction in PINK1
knock-out mice [31].
A large body of literature documents that mutations of PINK1
gene are associated with mitochondrial dysfunction. In particular,
complex I deficiency [24] [32] has been characterized as a
mechanism of energy balance failure [33] resulting also in
dramatic loss of dopaminergic neurons [34]. Although in the
present study we did not attempt any direct measurement of
mitochondrial energy impairment, this dysfunction was indirectly
determined by assessing the number of damaged, swollen and with
clearly fragmented cristae, mitochondria and we found that 0.1%
Mpe administration could dramatically recover their morphology
to that of WT controls (Fig. 5). This indicates that Mpe may play
beneficial actions by interfering with the mechanisms responsible
of energy production [24] or linked to maintenance of membrane
gradients as well as to protection against the raise of reactive
oxygen species within mitochondria [16]. In this regard, it is
intriguing to observe that Mp has antioxidant properties [35] and
it was suggested that its ‘‘rescue’’ properties may be due to
increased complex-I activity and presence of nicotinamide adenine
dinucleotide and coenzyme Q-10 [25]. This interpretation is also
supported by the observation that also enhancement of nucleotide
production, by feeding PINK1 mutant Dm with folic acid, results
in rescued loss of mitochondrial mass and function [31]. Thus, on
the basis of these reports and of our results it seems possible to
speculate that Mpe administration interferes with the pathway
regarding the mitochondrial rescue from oxidative stress but not
on the complex apoptosis mechanism. In fact, the clock of the end
of the life is not modified as also suggested by the results regarding
Figure 4. Effects ofMpe and L-Dopa on olfactory behavior. Responses to 1-hexanol 0.1% and water (H2O) of WT, untreated PINK1
B9 and inMpe
(0.1%)- and L-Dopa (0.01%)-treated PINK1B9 flies. Values are average + SEM. *indicates p,0.05 at two-way ANOVA followed by HSD post hoc test as
compared to WT, PINK1B9 Mpe 0.1%, PINK1B9 L-Dopa 0.01%.
doi:10.1371/journal.pone.0110802.g004
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the effect of Mpe on life span according to which the amelioration
is slight, albeit significant. In agreement with Poddighe et al. [4],
PINK1B9 mutants showed steeper slope life span curves and
overall shortened lifespan with respect to WT. Mpe significantly
attenuated these conditions only when administered to L+/A+ at
0.1%, but not when administered to adults only (L2/A+) no matter
the concentration tested (Fig. S1A), nor when administered with
0.01% L-Dopa. These results can be explained by taking into
account that in Drosophila the cluster of neurons is manly
conserved from larval to adult stage [28]. Conversely in L+/A+
mutants treated at the highest concentration administered (1–10%)
even if not significant, a worsening trend was observed (Fig. S1B).
The effects of Mpe on flies’ lifespan resemble those of the Mpe
component, nicotine, described in a Drosophila autosomal
recessive-juvenile model of parkinsonism [29].
Figure 5. Effects of Mpe on T-bars and mitochondria in antennal lobes and thoracic ganglia. Transmission electron microscopy (TEM)
images of T-bars and mitochondria inside antennal lobes (ALs) of wild type (WT), untreated PINK1B9 and in Mpe (0.1%)-treated PINK1B9 flies. (A): T-bars
in a presynaptic bouton of PINK1B9 ALs (arrowheads). Asterisks indicate mitochondria inside presynaptic boutons and neurites. Inset: high
magnification of two T-bar in coronal section. (B): T-bars in presynaptic boutons of ALs of PINK1B9 Mpe 0.1% (arrowheads). Asterisks indicate
mitochondria inside presynaptic boutons and neurites. (C): swelling on the external mitochondrial membrane (at high magnification in the inset) and
mitochondrial cristae widely degenerated (asterisks) in ALs of PINK1B9. (D): Mitochondria of PINK1B9 Mpe 0.1% (asterisks). (E): Presynaptic T-bar density
in ALs of WT, PINK1B9 and PINK1B9 0.1% Mpe flies. Values are average + SEM. *indicates p,0.01 at two tailed t-test with respect to PINK1B9. (F): T-bar
density in thoracic ganglia of WT, PINK1B9 and PINK1B9 0.1% Mpe flies. Values are average + SEM. *indicates p,0.01 at two tailed t-test with respect to
PINK1B9. (G): Percentages of damaged mitochondria in ALs of WT, PINK1B9 and PINK1B9 0.1% Mpe flies. Values are average + SEM. *indicates p,0.01 at
two tailed t-test with respect to PINK1B9. Abbreviations: postsyn: postsynaptic; presyn: presynaptic. Scale bars are 200 mm in A and B and 500 mm in C
and D.
doi:10.1371/journal.pone.0110802.g005
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In addition to the observed rescue of damaged mitochondria in
PINK1B9 mutants treated with 0.1% Mpe, we observed that this
treatment significantly recovered the expression of BRP and the
reduction of T-bars density in both PINK1B9 ALs and thoracic
ganglia, strengthening the tenet that BRP is crucial for the correct
formation of T-bars at active zones [36]. Mutation-induced
mitochondrial degeneration may also have led to the observed
diminished expression of BRP, known to be critical also for
neurotransmitter release [37] [38]. Accordingly, PINK1B9
mutants show degeneration of flight muscle and of dopaminergic
neurons accompanied by locomotive defects [23] [39] [40].
Humphrey et al. [40] also showed that climbing deficit is related
to dysfunction of dopaminergic cells and we found that PINK1B9
mutants also showed compromised motor capabilities as assessed
by climbing behavior (Fig. 2). Hence, Mpe-increased expression of
BRP may have increased the ability to release neurotransmitters
that would result in improved locomotion, as suggested by
Yellman et al. [41]. Therefore, our data suggest that the effects
of Mpe treatment on BRP expression, climbing and T-bars in
PINK1B9 mutants may represent the convergence toward an
unified mechanism grounded on mitochondria functional rescue.
Olfactory dysfunction is a clinical early non-motor symptom of
PD [3] and, accordingly, we observed loss of olfaction in PINK1B9
mutant Dm [4]. The physiopathology of olfactory dysfunction is
not known. However, many studies have suggested involvement of
dopaminergic system [42] [43]. In our investigation we observed
improved olfactory responsiveness underlined by both behavioral
and electrophysiological experiments.
It is interesting to observe that the shape of EAG responses
recorded in the WT revealed a dose-related hyperpolarizing part
(Fig. S2). This observation seems in accordance with the
stimulating power of 1-hexanol that is reported to involve both
the appetitive and the aversive stimuli [19]. The EAG represent
the summed activity of all antennal sensory neurons involved in
stimulation. This activity can result in the EAG recordings in a
depolarization and/or hyperpolarization signal, that is elicited
according to the stimulating effect of the odor tested as well as of
its concentration. In details, in WT strain, the rapid depolarization
is followed by a slow recovery phase at the lower concentration
(0.01%) while at the highest concentration (1%), a greater
hyperpolarizing phase was recorded. This phase could represent
the activation of a pool of receptors that hyperpolarize when
stimulated at this high concentration. With regards to this, a
similar response was not present in untreated PINK1B9 (Fig. S2).
Future electrophysiological analysis of the olfactory response
should take into account both shape and amplitude whose
Figure 6. Effects of Mpe and L-Dopa on BRP and TH. (A): Representative western blot analysis of head homogenates from adult wild type (WT),
untreated PINK1B9 and in Mpe (0.1%)- and L-Dopa (0.01%)-treated PINK1B9 flies showing labeled bands of Bruchpilot protein (BRP), of Tyrosine
hydroxylase (TH) and of the loading control actin (from top to bottom). (B): Percentage of protein expression variation of BRP and TH in WT, untreated
PINK1B9 and in Mpe (0.1%)- and L-Dopa (0.01%)-treated PINK1B9 flies. Values are average + SEM. *indicates p,0.05 at one-way ANOVA with respect to
WT; **indicates p,0.05 at one-way ANOVA (HSD post-hoc test) with respect to PINK1B9 Mpe 0.1%.
doi:10.1371/journal.pone.0110802.g006
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variations might be a promising tool to study peripheral olfactory
responses. Furthermore, our behavioural results show that
PINK1B9 mutants have a decreased responsiveness to 1-hexanol
and water (Fig. 4) that reveals an impairment of also other
chemoreceptors such as hygroreceptors [44]. In other words the
mutants seem to present a general sensory impairment.
In agreement with study by Katzenschlager and Lees [45],
suggesting a possible association between olfaction, increased TH
and dopamine in the olfactory bulbs, we observed that PINK1B9
mutation-dependent impairment of olfaction behavior and whole
brain TH expression were improved by Mpe treatment (Figs. 4
and 6, respectively). Surprisingly, L-Dopa administration on its
own failed to recover TH expression to WT controls levels.
However, since our analysis was done in whole brain homoge-
nates, if analysis was restricted to the ALs, the homologous
structures of human olfactory bulbs, we cannot exclude the
possibility that L-Dopa would have brought different results.
The physiopathology of LID is still largely unknown and LID
has consistently been related to excessive DA release [46].
Furthermore, in parkinsonian non-human primates [47], L-Dopa
produces LID without enhancing striatal DA release. Interestingly,
Katzenschlager et al. [26] observed a reduced severity of
dyskinesias after Mp as compared to levodopa/carbidopa combi-
nation and an increased DDC expression associated with LID has
been reported in rats [48]. This intriguing prospective remains to
be fully demonstrated in the Dm mutant model. In conclusion, our
study confirms in this translational model the validity of Mucuna
pruriens as a valuable approach for PD treatment, discloses
mechanistic insights at the basis of its effects and confirms the use
of PINK1B9 Dm as a model of PD that fulfills the required face,
construct and predictive validity criteria to follow up on these
investigations.
Supporting Information
Figure S1 Effects of Mpe administered at different
concentration on lifespan. (A): Lifespan, expressed as %
survival rates of untreated and Mpe-treated PINK1B9 at the 4
dose-step tested: 0, 0.1, 1 and 10% (w/w) only when adults (L2/
A+). (B): lifespan of untreated and Mpe-treated PINK1B9 at the 4
dose-step tested: 0, 0.1, 1 and 10% (w/w) only when adults (L+/
A2).
(TIF)
Figure S2 EAGs samples. Dose-response relationships for
olfactory stimulations in WT and PINK1B9 adult flies and their
differences in signal amplitude and shape.
(TIF)
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